Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Long-term Activity Ratios (Summary)

Johnson & Johnson, long-term (investment) activity ratios (quarterly data)

Microsoft Excel
Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Net fixed asset turnover
Total asset turnover
Equity turnover

Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


An examination of the investment activity ratios reveals generally declining trends across the observed period, though with some quarterly fluctuations. The ratios indicate how efficiently assets are being utilized to generate revenue. Overall, the company demonstrates a consistent ability to generate sales relative to its investments, but the efficiency appears to be gradually decreasing.

Net Fixed Asset Turnover
The net fixed asset turnover ratio began at 5.07 and generally increased through the third quarter of 2022, peaking at 5.29. A subsequent decline was observed in the fourth quarter of 2022, falling to 4.79. This downward trend continued into 2023, reaching a low of 4.28 in the fourth quarter. The ratio experienced a slight recovery in the first quarter of 2024, but has generally trended downwards since, settling at 4.07 in the final quarter of the observed period. This suggests a decreasing efficiency in generating sales from fixed assets.
Total Asset Turnover
The total asset turnover ratio exhibited a similar pattern to the net fixed asset turnover. It started at 0.53 and increased slightly to 0.55 by the third quarter of 2022 before decreasing to 0.51 in the fourth quarter. The ratio continued to decline through the first half of 2023, reaching 0.47. A modest increase to 0.53 was seen in the third quarter of 2023, but the ratio subsequently decreased again, ending at 0.47 in the final quarter of the observed period. This indicates a diminishing ability to generate sales from all assets.
Equity Turnover
The equity turnover ratio showed less pronounced fluctuations than the other two ratios. It began at 1.27 and experienced minor variations, peaking at 1.30 in the first quarter of 2023. A consistent downward trend was observed from the second quarter of 2023, with the ratio falling to 1.14 in the first quarter of 2025. It stabilized somewhat in subsequent quarters, ending at 1.16 in the final quarter of the observed period. This suggests a decreasing ability to generate sales relative to shareholder equity.

In summary, the observed trends suggest a gradual decrease in the efficiency with which the company utilizes its assets and equity to generate revenue. While the ratios remain positive, the consistent downward movement warrants further investigation to determine the underlying causes and potential implications for future performance.


Net Fixed Asset Turnover

Johnson & Johnson, net fixed asset turnover calculation (quarterly data)

Microsoft Excel
Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Sales to customers
Property, plant and equipment, net
Long-term Activity Ratio
Net fixed asset turnover1
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q4 2025 Calculation
Net fixed asset turnover = (Sales to customersQ4 2025 + Sales to customersQ3 2025 + Sales to customersQ2 2025 + Sales to customersQ1 2025) ÷ Property, plant and equipment, net
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The net fixed asset turnover ratio exhibits a generally declining trend over the observed period, although with some fluctuation. Initially, the ratio demonstrated an increase from 5.07 to 5.29 between April 2022 and October 2022. Subsequently, it decreased to 4.79 by December 2022, and continued to fall to a low of 4.13 in both July 2023 and September 2023.

Overall Trend
A consistent downward trajectory is apparent when comparing the beginning and end of the period. The ratio moved from 5.07 in April 2022 to 4.07 in December 2025, representing a decrease of approximately 19.7%. This suggests a diminishing efficiency in generating sales revenue from the company’s net fixed assets.
Short-Term Fluctuations
Despite the overall decline, the ratio experienced some short-term increases. A notable rise occurred between July 2023 (4.13) and June 2024 (4.38). A further, albeit smaller, increase was observed between September 2024 (4.28) and December 2024 (4.33). These temporary improvements suggest potential operational efficiencies or shifts in sales patterns during those specific quarters.
Recent Performance
The most recent quarters show a slight stabilization, with the ratio fluctuating between 4.13 and 4.38 from July 2023 through December 2024. However, the final reported value for March 2025 (4.28) and June 2025 (4.13) indicate a continuation of the downward trend. The ratio concludes the period at 4.07 in December 2025.

The observed trend warrants further investigation to determine the underlying causes. Potential factors could include increased investment in fixed assets without a corresponding increase in sales, a decline in sales revenue, or changes in the composition of fixed assets. A deeper analysis, considering industry benchmarks and company-specific strategies, is recommended.


Total Asset Turnover

Johnson & Johnson, total asset turnover calculation (quarterly data)

Microsoft Excel
Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Sales to customers
Total assets
Long-term Activity Ratio
Total asset turnover1
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q4 2025 Calculation
Total asset turnover = (Sales to customersQ4 2025 + Sales to customersQ3 2025 + Sales to customersQ2 2025 + Sales to customersQ1 2025) ÷ Total assets
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The total asset turnover ratio exhibits a generally stable, yet slightly declining trend over the observed period. Initial values indicate a ratio fluctuating between 0.53 and 0.55 during the first four quarters, before settling into a range of approximately 0.46 to 0.53 for the subsequent twelve quarters.

Initial Period (Apr 3, 2022 – Dec 31, 2022)
The ratio begins at 0.53 and peaks at 0.55 before decreasing to 0.51 by the end of 2022. This initial fluctuation suggests a relatively consistent utilization of assets to generate sales, with a minor dip in efficiency towards the year-end.
Subsequent Decline (Apr 2, 2023 – Dec 28, 2025)
From early 2023 onward, the ratio generally trends downward, remaining largely between 0.46 and 0.53. The lowest observed value is 0.46 in the first quarter of 2025. While fluctuations occur, a clear downward trajectory is not present; rather, the ratio appears to stabilize within a lower range compared to the initial period. The most recent value, 0.47, suggests a continued level of asset utilization, but slightly lower than earlier periods.
Recent Stability
The last six quarters (Mar 30, 2025 – Dec 28, 2025) show the ratio oscillating between 0.47 and 0.48, indicating a period of relative stability in asset utilization. This suggests that changes in sales are broadly proportional to changes in total assets during this timeframe.

Overall, the observed trend suggests a slight decrease in the efficiency with which assets are being used to generate sales. However, the ratio remains within a reasonable range, and the recent stabilization indicates that this decline may have leveled off. Further investigation into the underlying drivers of sales and asset composition would be necessary to determine the cause of this trend and its potential implications.


Equity Turnover

Johnson & Johnson, equity turnover calculation (quarterly data)

Microsoft Excel
Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Sales to customers
Total Johnson & Johnson shareholders’ equity
Long-term Activity Ratio
Equity turnover1
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q4 2025 Calculation
Equity turnover = (Sales to customersQ4 2025 + Sales to customersQ3 2025 + Sales to customersQ2 2025 + Sales to customersQ1 2025) ÷ Total Johnson & Johnson shareholders’ equity
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The equity turnover ratio for the analyzed period demonstrates a generally stable pattern with some fluctuation. Initially, the ratio exhibited a slight decline from 1.27 to 1.24 between April 2022 and December 2022. A subsequent increase to 1.30 was observed in April 2023, followed by a decrease to 1.20 in July 2023. The ratio then recovered modestly, fluctuating between 1.21 and 1.25 over the subsequent six quarters. The most recent quarters show a slight downward trend, with the ratio decreasing from 1.25 in September 2024 to 1.16 in December 2025.

Overall Trend
The equity turnover ratio has remained relatively consistent throughout the analyzed period, generally ranging between 1.14 and 1.30. While fluctuations occur, there is no strong evidence of a sustained upward or downward trend over the entire timeframe. The latter part of the period suggests a possible, albeit slight, decline.
Short-Term Fluctuations
A notable increase in the ratio occurred between December 2022 (1.24) and April 2023 (1.30). This suggests a period of increased efficiency in utilizing shareholder equity to generate sales. Conversely, the drop from April 2023 (1.30) to July 2023 (1.20) indicates a temporary decrease in this efficiency. Similar, smaller fluctuations are observed throughout the remaining period.
Recent Performance
The final four quarters show a consistent ratio of 1.16, indicating a stabilization at a lower level compared to the earlier part of the analyzed period. This could be due to a combination of factors, including changes in sales volume or equity levels. Further investigation would be needed to determine the underlying causes.
Relationship to Sales
Sales to customers generally increased over the period, but the equity turnover ratio did not consistently follow this trend. This suggests that increases in sales were often accompanied by increases in shareholder equity, mitigating the impact on the turnover ratio. The slight decline in the ratio towards the end of the period, despite continued sales growth, warrants further scrutiny.
Relationship to Equity
Total shareholder equity generally increased throughout the period, with some quarterly declines. The fluctuations in the equity turnover ratio appear to be partially influenced by these changes in equity. For example, the increase in equity between July 2023 and December 2023 coincided with a relatively stable equity turnover ratio.